1. Introduction {#s0005}
===============

Considerable data support the phenomenological and temporal continuity between psychotic disorders and subclinical manifestations of psychotic symptoms. Subclinical psychotic symptoms are common in the general population with an estimated prevalence of 7.2% and an annual incidence of 2.5% ([@bb0140]). The continuity between subclinical psychosis and psychotic disorders is supported by longitudinal studies demonstrating that high levels of subclinical psychotic symptoms predate the onset of psychotic illness ([@bb0030], [@bb0035], [@bb0055], [@bb0080], [@bb0175], [@bb0230]) as well as studies demonstrating substantial overlap in genetic predisposition for clinical and subclinical levels of psychotic symptoms ([@bb0115], [@bb0185], [@bb0210]). Moreover, a recent review and meta-analysis of the literature on subclinical psychosis spanning over 2 decades ([@bb0140]) found that nearly all of the demographic and experiential risk factors for psychotic disorders predicted greater risk of subclinical psychosis.

Over the last several decades, deficits across a range of cognitive skills have increasingly been recognized as a core feature of psychotic illness (e.g. [@bb0005]) but to date, only a limited number of studies have examined whether similar deficits are associated with subclinical psychosis in non-clinical samples. Data derived from studies of patients with schizotypal personality disorder (SPD), however, have reported considerable overlap in the neurocogntive deficits observed in SPD relative to schizophrenia (SZ) ([@bb0190] for a review). Because SPD is believed to represent an underlying predisposition for SZ or "psychosis-proneness" ([@bb0040]), these data suggest that neurocogntive deficits may be present across the lower ends of the psychosis continuum.

Studies examining the relationship between subclinical psychosis and neurocognitive functioning in non-clinical samples have yielded inconsistent results and have been limited in terms of the cognitive domains assessed ([@bb0060]). For example, [@bb0220] found that in males, but not females, deficits in verbal fluency were associated with severity of overall levels of subclinical psychosis. However, these authors did not assess other domains of cognitive function. Contrary to the sex effect reported by [@bb0220], [@bb0195] measured speed of processing and verbal learning in an all female sample and found a significant association between both positive and negative subclinical symptoms and decreased speed of processing. [@bb0130] examined only set-shifting with the Wisconsin Card Sorting Test (WCST) and concluded that first-degree relatives of patients with SZ who had high scores of negative schizotypy on the Chapman scales scored significantly worse than relatives who had low scores and worse than healthy controls. Finally, [@bb0010] recently investigated whether childhood cognitive function was associated with adult subclinical psychotic symptoms in a large prospective birth cohort. They found that general cognitive ability (g) assessed at age 8, 11 and 15 was significantly predictive of subclinical psychotic symptoms in middle age. Specifically, lower cognitive scores were associated with a greater likelihood of endorsing subclinical psychotic symptoms. In this study, however, the association between current cognitive function and endorsement of subclinical psychotic symptoms was not assessed.

Several limitations of the aforementioned studies should be noted. First, most of these studies did not examine the effects of subclinical positive and negative symptoms separately. Cross-sectionally, the relationship between symptom severity and cognitive impairment in patients with SZ suggests that negative symptoms are more closely related to cognitive deficits than positive symptoms ([@bb0085]). Thus, it is possible that the mixed findings on the relationship between subclinical psychosis and cognitive function are related, in part, to the focus on overall levels of subclinical psychosis. Additionally, the cognitive domains examined have been limited and do not provide a comprehensive assessment of the relation between subclinical psychosis and cognitive function across the full range of domains typically observed to be impaired in SZ.

Thus, the goal of the present study was to examine this relationship in a large and demographically diverse non-clinical sample comprehensively characterized for the presence of subclinical psychotic symptoms and comprehensively assessed for neurocogntive performance. Specifically, we aimed to evaluate whether the presence of high levels of subclinical positive or negative symptoms as measured by the Community Assessment of Psychic Experiences (CAPE) ([@bb0205]) would be associated with differential performance across the 7 neurocognitive domains assessed by the MATRICS Consensus Cognitive Battery (MCCB) ([@bb0120]).

2. Method {#s0010}
=========

2.1. Participants {#s0015}
-----------------

The present sample comprised 303 healthy adult volunteers (53.13% female, 60.40% Caucasian, *M*~age~ = 38.12 ± 14.29 years, *M*~IQ~ (based on WRAT-3 Reading) = 103.14 ± 8.43) recruited from the general population via word of mouth, newspaper and internet advertisements and posted flyers for an NIMH-funded study of subclinical psychosis in the general population (MH086756 to PD). Participants were excluded if they had a past or present affective or psychotic disorder diagnosis, active or recent substance abuse, or if they had a history of CNS trauma, neurological disorder, or previously diagnosed learning disability.

2.2. Diagnostic assessments {#s0020}
---------------------------

Participants were initially administered the Structured Clinical Interview for the DSM-IV, Non-Patient edition (SCID-I/NP) to rule out a past or present affective or psychotic disorder. Information obtained from the SCID was compiled into a narrative case summary and lifetime diagnosis was determined by two senior members of the ZHH faculty.

2.3. Assessment of subclinical psychosis {#s0025}
----------------------------------------

Participants were administered the Community Assessment of Psychic Experiences (CAPE) ([@bb0205]), a 42-item, self-report questionnaire that measures three dimensions of subclinical psychopathology including positive, negative and depressive symptoms. In the present study, the positive and negative frequency dimensions were examined for relation to neurocogntive functioning. Consistent with prior reports ([@bb0225]), the positive and negative subscale scores derived from the CAPE were not normally distributed. Indeed, inspection of the data in our sample indicated that the CAPE subscale scores produced a half-normal distribution. Thus, because standard statistical techniques could not be utilized, we chose to dichotomize the subscale scores to facilitate the use of parametric tests. Initially, scores were divided into quartiles for both the negative and positive dimensions of subclinical psychotic symptoms. Any participant with a score at or above the 75th percentile was assigned to the high symptom group while those falling below the 75th percentile were assigned to the low symptom group. Thus, participants with a negative symptom subscale score greater than 20, representing on average, a score 1.23 standard deviations above the sample mean were considered to have high levels of negative symptoms. This score is consistent with participants experiencing several infrequent negative psychotic-like experiences or experiencing 2--3 recurrent experiences. Participants with a raw positive symptom subscale score greater than 24, representing on average, a score 1.10 standard deviations above the sample mean were considered to have high levels of positive symptoms. This score is consistent with participants experiencing several infrequent positive psychotic-like experiences or experiencing 1--2 recurrent experiences. It should also be noted that the CAPE provides a measure of the distress associated with the experience of positive and negative subclinical symptoms. In our data, these distress scores are highly correlated with the frequency scores (rho \> .9). Thus, these data were not examined as we believed they were redundant with analyses based on the frequency scores.

2.4. Neurocognitive assessment: the MCCB {#s0030}
----------------------------------------

To assess neurocognitive functioning, The MATRICS Consensus Cognitive Battery (MCCB) was administered to all participants. The MCCB is comprised of 10 standardized cognitive measures that collectively capture functioning within seven cognitive domains that are reliably impaired in schizophrenia ([@bb0160]) including: Speed of Processing, Attention/Vigilance, Working Memory, Verbal Learning, Visual Learning, Reasoning/Problem-solving, and Social Cognition. Participants in the current study completed the MCCB in one visit. In the present study, T scores, corrected for age and sex, derived from the MCCB scoring program were utilized as the primary dependent measures. Additionally, we utilized the Wide Range Achievement Test-Third Edition-Reading Subtest (WRAT-3) as an estimate of IQ. The WRAT-3 Reading subtest is a test that assesses single word reading skill and is highly correlated with full scale IQ ([@bb0125]).

2.5. Statistical analyses {#s0035}
-------------------------

We initially sought to rule out differences between participants with high and low levels of symptoms on age, sex, race and estimated IQ (based on WRAT-3 Reading subtest score). Thus, we utilized t-tests or chi square tests, as appropriate, to examine the distributions of these variables in those characterized as having high levels of positive symptoms vs. those with low levels of positive symptoms and in those characterized as having high levels of negative symptom vs. those with low levels of negative symptoms. Following these analyses, we carried out two multivariate analyses of covariance (MANCOVAs) comparing the high and low positive symptom groups and the high and low negative symptoms groups on all 7 MCCB domains. Because both race and general intelligence level have been shown to influence performance on the tests comprising the MCCB ([@bb0050], [@bb0155], [@bb0180]), racial group (white and non-white) and WRAT-3 Reading subtest standard score were included as covariates in these analyses. We did not include age and sex as covariates in these analyses because the MCCB T scores used as the dependent measures were corrected for these demographic variables a priori using the MCCB scoring program.

3. Results {#s0040}
==========

Comparison of the high and low positive symptom groups revealed no differences in age, sex, race or estimated IQ (all p's \> 0.19). These data are shown in [Table 1](#t0005){ref-type="table"}. The MANCOVA comparing the high and low positive symptom group revealed a significant overall effect (F(7,260) = 4.68; p \< 0.001) with post hoc tests indicating that participants with high levels of positive symptoms scored significantly *higher* than participants with low levels of positive symptoms on working memory (F(1,266) = 16.47; p \< 0.001), verbal learning (F(1,266) = 7.40; p = 0.007) and visual learning (F(1,266) = 6.11; p = 0.014). These data are shown in [Fig. 1](#f0005){ref-type="fig"}.Fig. 1Comparison of participants classified as high vs. low on subclinical positive psychotic symptoms across all 7 MCCB Domains. Mean T scores have been adjusted for race and WRAT-3 performance. Significant differences are indicated by an asterisk (\*).Table 1Participant demographics.Symptom DomainAge (SD)% FemaleWRAT-3 (SD)% MinorityPositive SymptomsHigh (N = 103)37.91 (14.27)48.54%104.02(8.48)44.66%Low (N = 200)38.53(14.40)55.5%102.68 (8.39)37.00%Negative SymptomsHigh (N = 92)38.91 (14.08)53.26%104.88 (7.41)[a](#tf0005){ref-type="table-fn"}35.87%Low (N = 211)37.77 (14.81)53.08%102.38 (8.74)41.23%[^1][^2]

It should be noted that some of our participants (N = 42) were still within the age range of risk for conversion to a psychotic disorder (i.e. \< 30 years old), which could have implications for cognitive functioning. Thus, to ensure that these results were not driven by a subset of participants who could potentially transition to a psychotic disorder, we removed participants under that age of 30 and re-ran the MANCOVA. The results of this analysis were identical to the results obtained in the full sample. Additionally, because negative symptoms are generally highly correlated with positive symptoms in both clinical and non-clinical samples ([@bb0140]), we followed up this analysis by examining 1) the relation between positive and negative symptoms subscale scores and 2) the effect of including the negative symptom subscale score as a covariate in the original MANCOVA comparing the high and low positive symptom groups. In these analyses, the positive symptom and negative symptom subscales were highly correlated (rho = .59; p \< 0.001). Moreover, although the MANCOVA remained significant (F(7,259) = 2.45; p = 0.02), the post hoc tests indicated that the difference between groups was no longer significant in the visual learning domain. The differences in working memory and verbal learning however, remained significant (p = 0.004 and p = 0.03, respectively). Finally, to confirm that these findings were not an artifact of the method we used to dichotomize our sample, we also examined the correlations between the raw CAPE positive symptom subscale score and T scores for the working memory and verbal learning domain. These analyses indicated the CAPE positive symptom subscale was positively correlated with both working memory (rho = 0.14; p = 0.02) and verbal learning (rho = 0.12; p = 0.04).

Comparison of the high and low negative symptom groups revealed no differences in age, sex or race (all p's \> 0.38). Comparison of the high and low negative symptom groups on our measure of estimated IQ, however, indicated that participants with high levels of negative symptoms had significantly *better* WRAT-3 Reading subtest standard scores than those participants who had low levels of negative symptoms (t = 2.38, p = 0.02). These data are shown in [Table 1](#t0005){ref-type="table"}. The MANCOVA comparing the high and low negative symptom groups across the 7 MCCB domains revealed no significant overall effect. These data are shown in [Fig. 2](#f0010){ref-type="fig"}.Fig. 2Comparison of participants classified as high vs. low on subclinical negative psychotic symptoms across all 7 MCCB Domains. Mean T scores have been adjusted for race and WRAT-3 performance. No significant differences were found for any of the MCCB domains.

In the present sample of 303 participants 47 participants were classified as high in both positive and negative subclinical symptoms. Comparison of these participants to those characterized as low in both symptom domains (N = 150) using a MANCOVA identical to the primary analyses, revealed that those with high levels of both subclinical positive and negative symptoms performed significantly better in the domains of working memory (p \< 0.001) and visual learning (p = .036) and trended toward better performance in the verbal learning domain (p = 0.053).

Finally, to demonstrate that those in the high symptom groups were exhibiting symptoms that could be considered clinically relevant, we assessed a sample of stable outpatients with schizophrenia or schizoaffective disorder (N = 184) recruited to an NIMH-funded study of functional disability using the CAPE. We have previously demonstrated that scores obtained on the CAPE in patient samples are valid and converge with those derived from clinician-administered assessment scales ([@bb9000]). Using this sample, which is well matched in age and sex to the control sample in the present study, we compared the raw CAPE scores in 1) our high positive symptom group to patients scoring within the lower half of the distribution on the raw CAPE positive symptom score and 2) our high negative symptom group to patients with scoring within the lower half of the distribution on the raw CAPE negative symptom score. In the positive symptom analysis, the mean rank of the controls was significantly *higher* than the mean rank of the patients (mean rank controls = 121.89 vs. mean rank patients = 75.22; p \< 0.001). Similarly, in the negative symptom analysis, the mean rank of the controls was significantly *higher* than the mean rank of the patients (mean rank controls = 119.58 vs. mean rank patients = 50.00; p \< 0.001). These data suggest that the symptom levels experienced by participants characterized as having "high" subclinical symptoms are very similar to the mild symptoms observed in patients with psychotic disorders.

4. Discussion {#s0045}
=============

The present findings suggest that high levels of positive subclinical symptoms in participants with no history of an axis I psychotic or affective disorder are associated with significantly better performance on measures of working memory, verbal learning, and visual learning as measured by the MCCB. Moreover, although no effect of high negative symptoms was noted on MCCB performance, ancillary findings indicated that those who scored high on negative symptoms evidenced significantly better performance on a measure of estimated IQ (WRAT-3 Reading subtest). These results are at odds with several prior reports that have generally shown a negative relationship between neurocognitive functioning and severity of subclinical psychotic symptoms ([@bb0090], [@bb0130], [@bb0195], [@bb0220]).

Our findings suggest some potential discontinuities between clinically significant psychotic symptoms and sub-syndromal manifestations of psychosis. Specifically, if subclinical psychosis represents a milder manifestation of the psychotic symptoms observed in disorders such as SZ, we might expect to see cognitive impairment in the individuals exhibiting high levels of subclinical psychotic symptoms similar to, albeit less severe than, those observed in SZ. Indeed, it has generally been found that cognitive deficits consistently accompany clinically significant psychotic symptoms ([@bb0020], [@bb0135], [@bb0200]). Contrary to this expectation, however, we found *better* cognitive performance in individuals with high levels of subclinical psychosis.

One possible explanation for this discrepancy is that symptom severity bears a correlational, but not causative, relation to neurocognitive capacity. Support for this idea draws from a series of complementary findings that suggest higher cognitive capacities act as a resilience factor against clinically significant psychosis ([@bb0065], [@bb0075], [@bb0150]). First, patients with higher a priori cognitive capacities tend to have better functional outcomes than patients with lower cognitive capacities ([@bb0065], [@bb0075]). Moreover, the risk of transitioning from a prodromal state to a psychotic disorder is significantly associated with impaired neurocognitive function ([@bb0110]). Thus, when considering the population of individuals with high levels of subclinical psychosis, those with low a priori cognitive capacities would be expected to transition to clinically significant psychosis at a higher rate while those with higher cognitive capacities would be expected to pool in comparatively larger numbers in the subclinical domain because their high cognitive capacities protect them from transitioning. If this is the mechanism at work, then the results of the present study could be attributed to an inherent sampling bias. This conclusion would also suggest that the cognitive deficits observed in psychotic disorders such as SZ may be independent from the positive and negative symptoms characteristic of the illness. This is consistent with several lines of research suggesting that psychotic and cognitive symptoms may be separable and perhaps independent characteristics of SZ (see [@bb0085] for a review).

It is also possible, however, that there is a direct causative link between subclinical psychosis and increased cognitive function. Several studies seeking to elucidate why psychosis continues to persist despite the substantial decrements in reproductive fitness associated with it, have proposed that genetic variants associated with subclinical psychosis may be beneficial in some way. Several studies have suggested that some of the risk variants may be associated with heightened creativity or other intellectual abilities ([@bb0015], [@bb0025], [@bb0045], [@bb0070], [@bb0100], [@bb0105], [@bb9005] [@bb0145]). For example, [@bb0100] found that patient relatives, but not the patients themselves, had a significantly higher probability of being persons of eminence than people in the general population, and [@bb0070] reported that individuals with higher scores on a test of schizotypy produced the most creative responses on a divergent thinking battery.

Several limitations of the present study should be noted. First, because the scores obtained on the positive and negative symptom subscales of the CAPE were not normally distributed, we opted to use an extreme groups analysis ([@bb9010]), which has some inherent limitations. This approach may have limited our ability to detect more nuanced relationships between the level of subclinical psychotic symptoms and neurocognitive performance. Moreover, because participants in the overall sample were only excluded if they met criteria for a psychotic or mood disorder 16 participants met criteria for another axis I disorder (4 anxiety disorder NOS, 12 past substance abuse). However, to rule out the effects of these diagnoses on our findings we re-ran both of the primary MANCOVAs. The results of these analyses were identical to what was found in the larger sample suggesting that the observed differences were not driven by participants who met criteria for an axis I disorder. Despite these limitations, however, the present findings contribute to a growing literature seeking to elucidate the relationship between subclinical psychosis and neurocogntive functioning in otherwise healthy adults. Additional studies in larger samples are warranted.
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[^1]: *Note:* Scores for the Wide Range Achievement Test-Third Edition-Reading Subtest (WRAT-3) are presented as standard scores.

[^2]: Participants classified as high on subclinical negative symptoms score significantly higher on the WRAT-3 than those classified as low on negative symptoms (t ~(300)~ = 2.38; p = .02).
